Rachel Mickevich
Neurology · Scottsdale, AZNPI 1992949093
Payments from drug & device makers
Across 1,109 payments — averaging $20.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- UCB, Inc.$2K
- ZOLL Respicardia, Inc.$2K
- Jazz Pharmaceuticals Inc.$1K
- AstraZeneca$790
- Pfizer$710
- plus $14K from 54 others
What the payments were for
- Consulting fees$5002%
- Speaking & faculty fees$380%
- Travel & lodging$8674%
- Food & beverage$20,95592%
- Education$5072%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- remede System$1,472
- Inspire$227
- LUMRYZ$200
- TYSABRI$150
- XYWAV$150
- XYREM$150
- Briviact$124
- ACTIVA$121
- PERCEPT PC BRAINSENSE$118
How this compares
$22,867 in reported general payments places this provider in the 70th percentile of 388 neurology providers in Arizona.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nurtec OdtRimegepant Sulfate | 25 | $45,651 |
| UbrelvyUbrogepant | 19 | $25,539 |
| Aimovig AutoinjectorErenumab-Aooe | 30 | $22,370 |
| BelsomraSuvorexant | 40 | $17,044 |
| Emgality PenGalcanezumab-Gnlm | 11 | $7,517 |
| Gabapentin | 111 | $2,592 |
| Pregabalin ErPregabalin | 18 | $2,284 |
| Lacosamide | 36 | $1,862 |
| Rivastigmine | 11 | $1,837 |
| Pregabalin | 66 | $1,816 |
| Memantine Hcl | 57 | $1,556 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 34 | $1,452 |
| Oxcarbazepine | 19 | $1,234 |
| Duloxetine Hcl | 43 | $1,132 |
| Modafinil | 19 | $1,027 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerNurtec Odt | $710 | $45,65125 claims |
| AbbVieUbrelvy | $2,539 | $25,53919 claims |
| MerckBelsomra | $99 | $17,04440 claims |
| Upsher-smith Laboratories LLCTopiramate | $218 | $29129 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 388 neurology providers in Arizona.
Other neurology in Scottsdale
- Nida LaurinScottsdale$2.3M
- Allan BlockScottsdale$1.7M
- Virgilio Gerald EvidenteScottsdale$714K
- Brent GoodmanScottsdale$544K
- Dean WingerchukScottsdale$496K
- Meredith WicklundScottsdale$476K
- Erika Driver-DunckleyScottsdale$403K
- Amaal StarlingScottsdale$344K
- David SapersteinScottsdale$289K
- Maciej MrugalaScottsdale$243K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.